Last reviewed · How we verify

NCT07431606: Duloxetine in

Duloxetine in Inflammatory Bowel Diseases

Not yet recruiting Phase 2 Last updated 24 February 2026
What this trial tests

Phase 2 trial testing Duloxetine in Inflammatory Bowel Diseases in 32 participants. Not yet recruiting.

Timeline
1 March 2026
Primary endpoint
1 March 2027
31 October 2027

Quick facts

Lead sponsorUniversity of Pennsylvania
PhasePhase 2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment32
Start date1 March 2026
Primary completion1 March 2027
Estimated completion31 October 2027

Drugs / interventions tested

Conditions studied

Sponsor

University of Pennsylvania

Who can join

24 and older, any sex, with Inflammatory Bowel Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This open-label, prospective, single-arm pilot study investigates the use of duloxetine, a central neuromodulator, for improving psychological distress and functional impairment in adults with inflammatory bowel disease (IBD). The study focuses on patient-reported outcomes related to anxiety, depression, and IBD-related disability, aiming to assess feasibility, tolerability, and preliminary efficacy in modulating gut-brain axis symptoms and disease-related functional impairments in life

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Duloxetine

Trials testing the same drug.

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

Other University of Pennsylvania trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07431606.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing